• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Evinacumab - The new kid on the block. Is it important for cardiovascular prevention?

作者信息

Surma Stanisław, Romańczyk Monika, Filipiak Krzysztof J

机构信息

Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, Poland.

Club of Young Hypertensiologists, Polish Society of Hypertension, Poland.

出版信息

Int J Cardiol Cardiovasc Risk Prev. 2021 Sep 22;11:200107. doi: 10.1016/j.ijcrp.2021.200107. eCollection 2021 Dec.

DOI:10.1016/j.ijcrp.2021.200107
PMID:34988554
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8710419/
Abstract
摘要

相似文献

1
Evinacumab - The new kid on the block. Is it important for cardiovascular prevention?依维那单抗——新出现的事物。它对心血管疾病预防很重要吗？
Int J Cardiol Cardiovasc Risk Prev. 2021 Sep 22;11:200107. doi: 10.1016/j.ijcrp.2021.200107. eCollection 2021 Dec.
2
Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia.单克隆抗体抑制血管生成素样蛋白 3 可降低高甘油三酯血症中的甘油三酯。
Circulation. 2019 Aug 6;140(6):470-486. doi: 10.1161/CIRCULATIONAHA.118.039107. Epub 2019 Jun 27.
3
A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects.一项评估 ANGPTL3 抑制剂依维莫司安全性、耐受性和药代动力学的在健康日本和白种人群体中的随机研究。
Atherosclerosis. 2020 Dec;314:33-40. doi: 10.1016/j.atherosclerosis.2020.10.013. Epub 2020 Oct 10.
4
Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity.功能性分析 LDLR（低密度脂蛋白受体）变异在患者淋巴细胞中，以评估依维莫司在杂合子家族性高胆固醇血症患者中对 LDLR 活性谱的影响。
Arterioscler Thromb Vasc Biol. 2019 Nov;39(11):2248-2260. doi: 10.1161/ATVBAHA.119.313051. Epub 2019 Oct 3.
5
Evinacumab in Patients with Refractory Hypercholesterolemia.依洛尤单抗治疗难治性高胆固醇血症患者的疗效。
N Engl J Med. 2020 Dec 10;383(24):2307-2319. doi: 10.1056/NEJMoa2031049. Epub 2020 Nov 15.
6
Evinacumab for treatment of familial hypercholesterolemia.依洛尤单抗治疗家族性高胆固醇血症。
Expert Rev Cardiovasc Ther. 2021 Aug;19(8):739-751. doi: 10.1080/14779072.2021.1955349. Epub 2021 Jul 22.
7
Evinacumab for Homozygous Familial Hypercholesterolemia.依洛尤单抗治疗纯合子家族性高胆固醇血症。
N Engl J Med. 2020 Aug 20;383(8):711-720. doi: 10.1056/NEJMoa2004215.
8
Evinacumab: First Approval.依维莫司：首次批准。
Drugs. 2021 Jun;81(9):1101-1105. doi: 10.1007/s40265-021-01516-y. Epub 2021 May 18.
9
Marked plaque regression in homozygous familial hypercholesterolemia.家族性高胆固醇血症患者的斑块明显消退。
Atherosclerosis. 2021 Jun;327:13-17. doi: 10.1016/j.atherosclerosis.2021.04.014. Epub 2021 May 3.
10
Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice.阿利西尤单抗、依洛尤单抗和阿托伐他汀三联疗法可使小鼠的斑块病变消退，并改善病变成分。
J Lipid Res. 2020 Mar;61(3):365-375. doi: 10.1194/jlr.RA119000419. Epub 2019 Dec 16.

引用本文的文献

1
Current landscape of innovative drug development and regulatory support in China.中国创新药物研发与监管支持的现状
Signal Transduct Target Ther. 2025 Jul 22;10(1):220. doi: 10.1038/s41392-025-02267-y.
2
Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia.依维那库单抗，一种血管生成素样蛋白3抑制剂，用于治疗血脂异常。
J Clin Med. 2022 Dec 25;12(1):168. doi: 10.3390/jcm12010168.
3
Management of Familial Hypercholesterolemia with Special Emphasis on Evinacumab.家族性高胆固醇血症的管理，特别强调依维苏单抗。

本文引用的文献

1
ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia-Brief Report.依维莫司治疗杂合子家族性高胆固醇血症患者的疗效：初步报告。
Arterioscler Thromb Vasc Biol. 2021 May 5;41(5):1753-1759. doi: 10.1161/ATVBAHA.120.315204. Epub 2021 Mar 11.
2
Angiopoietin-like proteins inhibitors: New horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia.血管生成素样蛋白抑制剂：治疗动脉粥样硬化性血脂异常和家族性高胆固醇血症的新领域。
Cardiol J. 2023;30(1):131-142. doi: 10.5603/CJ.a2021.0006. Epub 2021 Jan 20.
3
Biomedicines. 2022 Dec 16;10(12):3273. doi: 10.3390/biomedicines10123273.
4
Personalized management of dyslipidemias in patients with diabetes-it is time for a new approach (2022).个体化管理糖尿病患者的血脂异常——是时候采用新方法了（2022 年）。
Cardiovasc Diabetol. 2022 Nov 28;21(1):263. doi: 10.1186/s12933-022-01684-5.
5
Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL.基于新型药物和营养保健品的心血管疾病预防方法：靶向致动脉粥样硬化的小而密低密度脂蛋白
Pharmaceutics. 2022 Apr 9;14(4):825. doi: 10.3390/pharmaceutics14040825.
Evinacumab in Patients with Refractory Hypercholesterolemia.
依洛尤单抗治疗难治性高胆固醇血症患者的疗效。
N Engl J Med. 2020 Dec 10;383(24):2307-2319. doi: 10.1056/NEJMoa2031049. Epub 2020 Nov 15.
4
A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects.一项评估 ANGPTL3 抑制剂依维莫司安全性、耐受性和药代动力学的在健康日本和白种人群体中的随机研究。
Atherosclerosis. 2020 Dec;314:33-40. doi: 10.1016/j.atherosclerosis.2020.10.013. Epub 2020 Oct 10.
5
Evinacumab for Homozygous Familial Hypercholesterolemia.依洛尤单抗治疗纯合子家族性高胆固醇血症。
N Engl J Med. 2020 Aug 20;383(8):711-720. doi: 10.1056/NEJMoa2004215.
6
Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia.单克隆抗体抑制血管生成素样蛋白 3 可降低高甘油三酯血症中的甘油三酯。
Circulation. 2019 Aug 6;140(6):470-486. doi: 10.1161/CIRCULATIONAHA.118.039107. Epub 2019 Jun 27.
7
New insights into angiopoietin-like proteins in lipid metabolism and cardiovascular disease risk.血管生成素样蛋白在脂代谢和心血管疾病风险中的新见解。
Curr Opin Lipidol. 2019 Jun;30(3):205-211. doi: 10.1097/MOL.0000000000000600.
8
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.血管生成素样蛋白3的基因和药物失活与心血管疾病
N Engl J Med. 2017 Jul 20;377(3):211-221. doi: 10.1056/NEJMoa1612790. Epub 2017 May 24.
9
The ANGPTL3-4-8 model, a molecular mechanism for triglyceride trafficking.血管生成素样蛋白3-4-8模型，一种甘油三酯转运的分子机制。
Open Biol. 2016 Apr;6(4):150272. doi: 10.1098/rsob.150272.